Target Name: MIR4723
NCBI ID: G100616388
Review Report on MIR4723 Target / Biomarker Content of Review Report on MIR4723 Target / Biomarker
MIR4723
Other Name(s): hsa-miR-4723-5p | MicroRNA 4723 | mir-4723 | hsa-mir-4723 | hsa-miR-4723-3p | microRNA 4723

MIR4723: A Potential Drug Target and Biomarker

MIR4723 is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique genetic makeup and expressed levels in various tissues make it an attractive target for researchers to study and develop new treatments.

The gene, which encodes a protein known as MIR4723, is located on chromosome 6p21. It is a non-coding RNA molecule that has been shown to be expressed in various tissues and organs, including brain, heart, liver, and muscle. The MIR4723 protein is a key regulator of gene expression and has been shown to play a role in the development and progression of various diseases.

One of the most promising aspects of MIR4723 is its potential as a drug target. The MIR4723 gene has been shown to be involved in several cellular processes that are associated with the development of disease, including inflammation, stress, and cellular signaling. Researchers are interested in using MIR4723 as a target for developing new treatments for a variety of conditions, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key challenges in developing MIR4723 as a drug target is its expression in different tissues and its expression level may vary depending on the disease state. Therefore, researchers have been working to study the expression of MIR4723 in different tissues and conditions to identify the most effective ways to target the gene and develop new treatments.

In addition to its potential as a drug target, MIR4723 has also been identified as a potential biomarker for several diseases. The MIR4723 gene has been shown to be expressed in various tissues and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. This makes it an attractive candidate for use as a biomarker for these diseases, as it may be possible to use MIR4723 as a diagnostic tool or to track the progress of disease.

One of the most promising aspects of using MIR4723 as a biomarker is its potential to identify new biomarkers for diseases that are currently untreated or have limited treatment options. For example, MIR4723 has been shown to be expressed in various tissues and conditions associated with cancer, including breast, ovarian, and colorectal cancers. This makes it an attractive candidate for use as a biomarker for these cancers and may help researchers identify new treatments for these deadly diseases.

Another promising aspect of MIR4723 is its potential to be used as a target for small molecules. The MIR4723 gene has been shown to be involved in several cellular processes that are associated with the development of disease, including inflammation, stress, and cellular signaling. This makes it an attractive candidate for use as a target for small molecules that can modulate these processes and potentially treat a variety of diseases.

In conclusion, MIR4723 is a gene that has been identified as a potential drug target and biomarker for various diseases. Its unique genetic makeup and expressed levels in various tissues make it an attractive target for researchers to study and develop new treatments. As more research is conducted on MIR4723, it is likely that researchers will uncover even more potential uses for this gene and its products.

Protein Name: MicroRNA 4723

The "MIR4723 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR4723 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR4724 | MIR4725 | MIR4726 | MIR4727 | MIR4728 | MIR4729 | MIR4730 | MIR4731 | MIR4732 | MIR4733 | MIR4734 | MIR4735 | MIR4736 | MIR4737 | MIR4738 | MIR4739 | MIR4740 | MIR4741 | MIR4742 | MIR4745 | MIR4746 | MIR4747 | MIR4749 | MIR4750 | MIR4751 | MIR4752 | MIR4753 | MIR4754 | MIR4755 | MIR4756 | MIR4757 | MIR4758 | MIR4759 | MIR4760 | MIR4761 | MIR4762 | MIR4763 | MIR4764 | MIR4765 | MIR4766 | MIR4767 | MIR4768 | MIR4769 | MIR4770 | MIR4771-1 | MIR4771-2 | MIR4772 | MIR4773-1 | MIR4773-2 | MIR4774 | MIR4775 | MIR4776-1 | MIR4776-2 | MIR4777 | MIR4778 | MIR4779 | MIR4780 | MIR4781 | MIR4782 | MIR4783 | MIR4784 | MIR4785 | MIR4786 | MIR4787 | MIR4789 | MIR4790 | MIR4791 | MIR4793 | MIR4794 | MIR4795 | MIR4796 | MIR4797 | MIR4798 | MIR4799 | MIR4800 | MIR4802 | MIR4803 | MIR4804 | MIR483 | MIR484 | MIR485 | MIR486-1 | MIR486-2 | MIR487A | MIR487B | MIR488 | MIR489 | MIR490 | MIR491 | MIR492 | MIR493 | MIR494 | MIR495 | MIR496 | MIR497 | MIR497HG | MIR498 | MIR4999 | MIR499A | MIR499B